TScan Therapeutics(TCRX) - 2025 Q1 - Quarterly Results

Financial Performance - Revenue for Q1 2025 was $2.2 million, a significant increase from$0.6 million in Q1 2024, primarily due to research activities under a collaboration agreement with Amgen[7]. - R&D expenses for Q1 2025 were $29.8 million, up from$24.9 million in Q1 2024, driven by increased laboratory supplies and personnel expenses[8]. - G&A expenses for Q1 2025 were $8.6 million, compared to$7.1 million in Q1 2024, mainly due to higher personnel costs[9]. - Net loss for Q1 2025 was $34.1 million, compared to a net loss of$30.1 million in Q1 2024, including net interest income of $2.1 million[10]. - Cash, cash equivalents, and marketable securities as of March 31, 2025, were$251.7 million, expected to fund operations into Q1 2027[12]. - As of March 31, 2025, the company had 129,678,572 shares outstanding, including pre-funded warrants[13]. Research and Development - The company plans to file an IND application for TSC-102-A0301 in the second half of 2025[11]. - TScan is on track to initiate a registrational trial for TSC-101 in the latter half of 2025[11]. - The first patient for multiplex TCR-T therapy is expected to be dosed in the first half of 2025[11]. - The company continues to develop the ImmunoBank for diverse TCR-T therapy candidates targeting various cancer-associated antigens[6].